Axel Schonthal, PhD

Title(s)Associate Professor of Molecular Microbiology & Immunology
SchoolKeck School of Medicine of Usc
AddressHMR 405A 2011 Zonal Avenue
Health Sciences Campus
Los Angeles CA 90089
Phone+1 323 442 1730
ORCID ORCID Icon0000-0003-0662-5653 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of Karlsruhe, GermanyPhDMolecular Biology
    UC San Diego, San Diego, CAPostdocCancer Biology

    Collapse Overview 
    Collapse overview
    The Schönthal lab performs preclinical cancer research and pursues anticancer drug development. The main focus is on brain malignancies, which include primary brain cancers (such as glioblastoma) and secondary brain cancers (such as melanoma or breast cancer that has spread to the brain). The work is done in collaboration with Dr. Thomas Chen, a neurosurgeon and Director of the USC Brain Tumor Group. This joint approach supports interdisciplinary efforts that translate laboratory findings to patient applications.

    Collapse ORNG Applications 
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Activation of Epstein-Barr Virus' Lytic Cycle in Nasopharyngeal Carcinoma Cells by NEO212, a Conjugate of Perillyl Alcohol and Temozolomide. Cancers (Basel). 2024 Feb 26; 16(5). Hartman-Houstman H, Swenson S, Minea RO, Sinha UK, Chiang MF, Chen TC, Schönthal AH. PMID: 38473298; PMCID: PMC10931041.
      View in: PubMed   Mentions: 2  
    2. From the groin to the brain: a transfemoral path to blood-brain barrier opening. Oncotarget. 2023 05 04; 14:413-416. Chen TC, Wang W, Schönthal AH. PMID: 37141417; PMCID: PMC10159364.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Intranasal Delivery of miR133b in a NEO100-Based Formulation Induces a Healing Response in Spinal Cord-Injured Mice. Cells. 2023 03 18; 12(6). Danilov CA, Thein TZ, Tahara SM, Schönthal AH, Chen TC. PMID: 36980272; PMCID: PMC10047048.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    4. NEO212, a Perillyl Alcohol-Temozolomide Conjugate, Triggers Macrophage Differentiation of Acute Myeloid Leukemia Cells and Blocks Their Tumorigenicity. Cancers (Basel). 2022 Dec 09; 14(24). Chen TC, Minea RO, Swenson S, Yang Z, Thein TZ, Schönthal AH. PMID: 36551551; PMCID: PMC9776529.
      View in: PubMed   Mentions: 6  
    5. The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers. Pharmaceutics. 2021 Dec 16; 13(12). Chen TC, da Fonseca CO, Levin D, Schönthal AH. PMID: 34959448; PMCID: PMC8709132.
      View in: PubMed   Mentions: 16  
    6. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro Oncol. 2021 10 01; 23(10):1656-1667. Wang W, He H, Marín-Ramos NI, Zeng S, Swenson SD, Cho HY, Fu J, Beringer PM, Neman J, Chen L, Schönthal AH, Chen TC. PMID: 33659980; PMCID: PMC8485439.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    7. Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia. Cancers (Basel). 2021 Jul 06; 13(14). Schönthal AH, Swenson S, Minea RO, Kim HN, Cho H, Mohseni N, Kim YM, Chen TC. PMID: 34298603; PMCID: PMC8305595.
      View in: PubMed   Mentions: 2  
    8. Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab005. Schönthal AH, Peereboom DM, Wagle N, Lai R, Mathew AJ, Hurth KM, Simmon VF, Howard SP, Taylor LP, Chow F, da Fonseca CO, Chen TC. PMID: 33604574; PMCID: PMC7879254.
      View in: PubMed   Mentions: 13  
    9. NEO100 enables brain delivery of blood‒brain barrier impermeable therapeutics. Neuro Oncol. 2021 01 30; 23(1):63-75. Wang W, Marín-Ramos NI, He H, Zeng S, Cho HY, Swenson SD, Zheng L, Epstein AL, Schönthal AH, Hofman FM, Chen L, Chen TC. PMID: 32877532; PMCID: PMC7850137.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    Axel's Networks
    Concepts (21)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (11)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.